Ticlopidine HCl Tablets Rx
Generic Name and Formulations:
Ticlopidine HCl 250mg; tabs.
Various generic manufacturers
Indications for Ticlopidine HCl Tablets:
To reduce the risk of thrombotic stroke in selected patients intolerant of aspirin.
250mg twice daily with food.
Hematopoietic disorders including neutropenia, thrombocytopenia, or history of thrombotic thrombocytopenic purpura (TTP). Hemostatic or active bleeding disorders. Severe hepatic impairment.
Monitor for hematologic toxicity at baseline, every 2 weeks for the first 3 months, and for 2 weeks after discontinuation; test more frequently if signs of hematological changes occur. Discontinue if neutropenia or TTP occur. Renal or hepatic impairment. Bleeding risk (eg, ulcers). Discontinue 10–14 days before surgery. Hyperlipidemia. Pregnancy (Cat.B). Nursing mothers: not recommended.
Discontinue anticoagulants, fibrinolytics before use. Avoid aspirin. Potentiates aspirin, NSAIDs, anticoagulants, antipyrine, theophylline. Antacids reduce absorption. May be potentiated by cimetidine. Monitor phenytoin. May antagonize digoxin. Caution with propranolol, drugs that increase risk of bleeding, and drugs metabolized by CYP450.
Platelet aggregation inhibitor.
Diarrhea, GI upset, rash, neutropenia, pruritus, dizziness, anorexia, abnormal liver function tests, bleeding complications, hyperlipidemia, TTP, aplastic anemia, agranulocytosis, other blood dyscrasis, jaundice.
Formerly known under the brand name Ticlid.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States